Visible Genetics Q3 Revenues Slip on Lower Product, Service Sales | GenomeWeb

NEW YORK, Nov. 13 – Visible Genetics of Toronto said Tuesday third-quarter revenues slipped slightly to $2.9 million, from $3.0 million in the year ago quarter, as product and service sales both fell.

On a positive note, Visible Genetics said that the US Food and Drug Administration had approved the company’s Trugene HIV-1 genotyping test for use in the clinical diagnostics market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.